Traws Pharma, Inc. received a notification from Nasdaq on July 29, 2026, indicating non-compliance with the Minimum Bid Price Requirement because its common stock closed below $1.00 per share for at least 30 consecutive business days. The listing remains effective as the company has until January 25, 2027, to regain compliance by maintaining a closing price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting proceedings. Traws Pharma operates in the biopharmaceutical industry, focusing on drug discovery and development.
